Dianthus Therapeutics, INC. /De/ (DNTH) — 8-K Filings

8-K Filings (13)

• Dianthus Therapeutics Files 8-K for 'Other Event' on March 26, 2026 — Mar 26, 2026
  Dianthus Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 8.01, indicating an 'Other Event' and including an exhibit EX-99.1. While the specific de
• Dianthus Therapeutics Files 8-K — Nov 3, 2025 Risk: low
  On November 3, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
• Dianthus Therapeutics Files 8-K — Oct 16, 2025 Risk: low
  Dianthus Therapeutics, Inc. filed an 8-K on October 16, 2025, reporting on the entry into a material definitive agreement, results of operations and financial c
• Dianthus Therapeutics Enters Material Definitive Agreement — Sep 11, 2025 Risk: medium
  Dianthus Therapeutics, Inc. announced on September 9, 2025, that it entered into a material definitive agreement. The company, formerly known as Magenta Therape
• Dianthus Therapeutics Files 8-K Report — Sep 8, 2025 Risk: low
  On September 8, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Finan
• Dianthus Therapeutics Files 8-K on Officer/Director Changes — May 22, 2025 Risk: medium
  Dianthus Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointmen
• Dianthus Therapeutics Appoints New CMO, Director — Mar 5, 2025 Risk: medium
  Dianthus Therapeutics, Inc. announced on March 4, 2025, a change in its board of directors. Specifically, Dr. Jonathan Jonathan, a director, resigned from his p
• Dianthus Therapeutics Files 8-K — Dec 12, 2024 Risk: low
  Dianthus Therapeutics, Inc. filed an 8-K on December 12, 2024, to report other events and financial statements. The company, formerly known as Magenta Therapeut
• Dianthus Therapeutics Appoints New Director — Sep 16, 2024 Risk: low
  Dianthus Therapeutics, Inc. announced on September 16, 2024, a change in its board of directors. Specifically, Dr. Jonathan Leff has been appointed as a Class I
• Dianthus Therapeutics Files 8-K for Disclosure — Jun 6, 2024 Risk: low
  Dianthus Therapeutics, Inc. (formerly Magenta Therapeutics, Inc.) filed an 8-K on June 6, 2024, to report a Regulation FD Disclosure and Financial Statements an
• Dianthus Therapeutics Announces Corporate Changes — May 28, 2024 Risk: medium
  Dianthus Therapeutics, Inc. announced on May 23, 2024, a series of significant corporate actions. These include the election of new directors, the appointment o
• Dianthus Therapeutics Reports Material Agreement, Unregistered Equity Sales — Jan 22, 2024
  Dianthus Therapeutics, Inc. filed an 8-K on January 22, 2024, to report an entry into a material definitive agreement and unregistered sales of equity securitie
• Dianthus Therapeutics Relocates HQ to NYC, Updates Phone — Jan 8, 2024
  Dianthus Therapeutics, Inc. filed an 8-K on January 8, 2024, to update its principal executive offices from Cambridge, MA to 7 Times Square, 43rd Floor, New Yor

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX